Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells - PubMed (original) (raw)
doi: 10.1038/sj.mt.6300157. Epub 2007 Apr 3.
Affiliations
- PMID: 17406343
- DOI: 10.1038/sj.mt.6300157
Free article
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells
Joseph Anderson et al. Mol Ther. 2007 Jun.
Free article
Abstract
Gene therapeutic strategies show promise in controlling human immunodeficiency virus (HIV) infection and in restoring immunological function. A number of efficacious anti-HIV gene constructs have been described so far, including small interfering RNAs (siRNAs), RNA decoys, transdominant proteins, and ribozymes, each with a different mode of action. However, as HIV is prone to generating escape mutants, the use of a single anti-HIV construct would not be adequate to afford long range-viral protection. On this basis, a combination of highly potent anti-HIV genes--namely, a short hairpin siRNA (shRNA) targeting rev and tat, a transactivation response (TAR) decoy, and a CCR5 ribozyme--have been inserted into a third-generation lentiviral vector. Our recent in vitro studies with this construct, Triple-R, established its efficacy in both T-cell lines and CD34 cell-derived macrophages. In this study, we have evaluated this combinatorial vector in vivo. Vector-transduced CD34 cells were injected into severe combined immunodeficiency (SCID)-hu mouse thy/liv grafts to determine their capacity to give rise to T cells. Our results show that phenotypically normal transgenic T cells are generated that are able to resist HIV-1 infection when challenged in vitro. These important attributes of this combinatorial vector show its promise as an excellent candidate for use in human clinical trials.
Similar articles
- Safety and Efficacy of a Lentiviral Vector Containing Three Anti-HIV Genes-CCR5 Ribozyme, Tat-rev siRNA, and TAR Decoy-in SCID-hu Mouse-Derived T Cells.
Anderson J, Li MJ, Palmer B, Remling L, Li S, Yam P, Yee JK, Rossi J, Zaia J, Akkina R. Anderson J, et al. Mol Ther. 2007 Jun;15(6):1182-1188. doi: 10.1038/sj.mt.6300157. Epub 2016 Dec 7. Mol Ther. 2007. PMID: 28182923 - RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model.
Bai J, Banda N, Lee NS, Rossi J, Akkina R. Bai J, et al. Mol Ther. 2002 Dec;6(6):770-82. doi: 10.1006/mthe.2002.0800. Mol Ther. 2002. PMID: 12498773 - Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages.
Banerjea A, Li MJ, Bauer G, Remling L, Lee NS, Rossi J, Akkina R. Banerjea A, et al. Mol Ther. 2003 Jul;8(1):62-71. doi: 10.1016/s1525-0016(03)00140-0. Mol Ther. 2003. PMID: 12842429 - siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS.
Akkina R, Banerjea A, Bai J, Anderson J, Li MJ, Rossi J. Akkina R, et al. Anticancer Res. 2003 May-Jun;23(3A):1997-2005. Anticancer Res. 2003. PMID: 12894572 Review. - RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy.
Li M, Li H, Rossi JJ. Li M, et al. Ann N Y Acad Sci. 2006 Oct;1082:172-9. doi: 10.1196/annals.1348.006. Ann N Y Acad Sci. 2006. PMID: 17145937 Review.
Cited by
- Optimal delivery of RNA interference by viral vectors for cancer therapy.
Wong B, Birtch R, Rezaei R, Jamieson T, Crupi MJF, Diallo JS, Ilkow CS. Wong B, et al. Mol Ther. 2023 Nov 1;31(11):3127-3145. doi: 10.1016/j.ymthe.2023.09.012. Epub 2023 Sep 20. Mol Ther. 2023. PMID: 37735876 Review. - Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies.
Buck AM, Deveau TM, Henrich TJ, Deitchman AN. Buck AM, et al. Viruses. 2023 May 9;15(5):1126. doi: 10.3390/v15051126. Viruses. 2023. PMID: 37243212 Free PMC article. Review. - Developments in Treatment Methodologies Using Dendrimers for Infectious Diseases.
Filipczak N, Yalamarty SSK, Li X, Parveen F, Torchilin V. Filipczak N, et al. Molecules. 2021 May 31;26(11):3304. doi: 10.3390/molecules26113304. Molecules. 2021. PMID: 34072765 Free PMC article. Review. - Targeting HIV-1 proviral transcription.
Olson A, Basukala B, Wong WW, Henderson AJ. Olson A, et al. Curr Opin Virol. 2019 Oct;38:89-96. doi: 10.1016/j.coviro.2019.07.011. Epub 2019 Aug 29. Curr Opin Virol. 2019. PMID: 31473372 Free PMC article. Review. - Lentivirus-mediated siRNA knockdown of SPHK1 inhibits proliferation and tumorigenesis of neuroblastoma.
Su L, Tian J, Sun J, Han N, Feng L, Yu B, Wang Y. Su L, et al. Onco Targets Ther. 2018 Oct 18;11:7187-7196. doi: 10.2147/OTT.S180962. eCollection 2018. Onco Targets Ther. 2018. PMID: 30425511 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- P01 AI061839/AI/NIAID NIH HHS/United States
- P30 AI054907/AI/NIAID NIH HHS/United States
- R01 AI057066/AI/NIAID NIH HHS/United States
- R01 AI50492/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources